Related Experiment Videos
Chemotherapy for localized, high-risk prostate cancer
Samir Narayan1, David C Smith, Howard M Sandler
1Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI 48109-0010, USA.
Seminars in Radiation Oncology
|May 3, 2003
Summary
Chemotherapy is established for hormone-refractory prostate cancer. Clinical trials are exploring if adding chemotherapy to hormone ablation and radiotherapy improves survival for advanced prostate cancer patients.
Area of Science:
- Oncology
- Urology
- Medical Research
Background:
- Chemotherapy is a standard treatment for hormone-refractory prostate cancer.
- Androgen ablation combined with radiotherapy shows survival benefits in poor-prognosis patients, possibly by targeting subclinical disease.
Purpose of the Study:
- To review the current role of chemotherapy in prostate cancer treatment.
- To discuss the potential survival advantage of combining chemotherapy with androgen ablation and radiotherapy.
- To explore the use of chemotherapy in nonmetastatic, hormone-naïve prostate cancer.
Main Methods:
- Review of existing clinical trials and evidence.
- Discussion of treatment strategies in prostate cancer management.
- Analysis of chemotherapy's efficacy in different prostate cancer stages.
Main Results:
- Chemotherapy is effective in hormone-refractory prostate cancer.
- Androgen ablation plus radiotherapy improves outcomes for high-risk patients.
- Ongoing trials investigate the adjunctive role of chemotherapy in hormone-sensitive settings.
Conclusions:
- Chemotherapy has a defined role in advanced prostate cancer.
- Further research is needed to establish chemotherapy's benefit in earlier, hormone-naïve prostate cancer.
- Combining therapies may offer survival advantages for specific patient groups.